Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Papp KA, et al. Among authors: stakias v. J Am Acad Dermatol. 2023 Dec;89(6):1149-1158. doi: 10.1016/j.jaad.2023.07.1024. Epub 2023 Aug 6. J Am Acad Dermatol. 2023. PMID: 37553030 Free article. Clinical Trial.
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L. Armstrong AW, et al. Among authors: stakias v. Dermatol Ther (Heidelb). 2022 Dec;12(12):2867-2870. doi: 10.1007/s13555-022-00812-z. Epub 2022 Oct 21. Dermatol Ther (Heidelb). 2022. PMID: 36271222 Free PMC article. No abstract available.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Among authors: stakias v. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Carter K, Stakias V, Lippe R, Drogaris L, Soliman AM, Chen MM, Padilla B, Kivitz A. Östör A, et al. Among authors: stakias v. Rheumatol Ther. 2024 Jun;11(3):633-648. doi: 10.1007/s40744-024-00657-2. Epub 2024 Mar 18. Rheumatol Ther. 2024. PMID: 38498139 Free PMC article.